CoChat

Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response

Open access
Felix, Joana, Lambert, Jérome, Roelens, Marie, Maubec, Eve, Guermouche, Hélène, Pages, Cécile, Sidina, Irina, Cordeiro, Debora J., Maki, Guitta, Chasset, François, Porcher, Raphaël, Bagot, Martine, Caignard, Anne, Toubert, Antoine, Lebbé, Céleste, Moins-Teisserenc, Hélène · 2016 · OncoImmunology

The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index, and 2 are not checked yet.

Abstract

PURPOSE: Therapy targeting CTLA-4 immune checkpoint provides increased survival in patients with advanced melanoma. However, immunotherapy is frequently associated with delayed and heterogeneous clinical responses and it is important to identify prognostic immunological correlates of clinical endpoints. EXPERIMENTAL DESIGN: 77 patients with stage III/IV melanoma were treated with ipilimumab alone every 3 weeks, during 9 weeks. Blood samples were collected at the baseline and before each dose for in depth immune monitoring. RESULTS: The median follow-up was 28 mo with a median survival of 7 mo. Survival and clinical benefit were significantly improved when absolute lymphocyte count at the baseline was above 1 × 10(9)/L. Notably, ipilimumab had a global effect on memory T cells, with an early increase of central and effector subsets in patients with disease control. By contrast, percentages of stem cell memory T cells (TSCM) gradually decreased despite stable absolute counts and sustained proliferation, suggesting a process of differentiation. Higher proportions of eomes(+) and Ki-67(+) T cells were observed, with enhanced skin homing potential and induction of cytotoxic markers. CONCLUSION: These results suggest that CTLA-4 blockade is able to reshape the memory subset with the potential involvement of Eomes and memory subsets including TSCM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1136045

Cites

57 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 32

Metadata

Authors
Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., Porcher, R., Bagot, M., Caignard, A., Toubert, A., Lebbé, C., & Moins-Teisserenc, H.
Affiliations
  • Inserm (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Toubert, Antoine
Venue
OncoImmunology
Published
2016-02-18
Volume
5
Issue
7
Pages
1136045
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2345485155
Cited by
32
References
56
Citations by year
2026: 2 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 6 · 2016: 2
FWCI
2.16
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Institut National de la Santé et de la Recherche Médicale
  • Université Paris Diderot
  • Institut National Du Cancer
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
ipilimumab, CTLA-4 blockade, melanoma, T cell memory subsets, stem cell memory T cells, central memory T cells, effector memory T cells, Eomesodermin, Ki-67, skin-homing T cells, immune checkpoint inhibitors, prognostic factors, absolute lymphocyte count, T cell differentiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. https://app.cochat.ai/papers/10.1080/2162402x.2015.1136045
The paper
Felix, J., Lambert, J., Roelens, M., Maubec, E., Guermouche, H., Pages, C., Sidina, I., Cordeiro, D. J., Maki, G., Chasset, F., Porcher, R., Bagot, M., Caignard, A., Toubert, A., Lebbé, C., & Moins-Teisserenc, H. (2016). Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1136045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.